LigaChem Biosciences Inc. Logo

LigaChem Biosciences Inc.

Clinical-stage biopharma developing ADCs, immuno-oncology drugs, and small molecules.

141080 | KO

Overview

Corporate Details

ISIN(s):
KR7141080002
LEI:
Country:
South Korea
Address:
대전광역시 유성구 국제과학10로 10 (주)레고켐 바이오사이언스, 대전광역시

Description

LigaChem Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative medicines. Leveraging its core expertise in medicinal chemistry, the company focuses on developing Antibody-Drug Conjugates (ADCs), immuno-oncology drugs, and small molecules. A key asset is its proprietary, next-generation ADC platform technology, engineered to overcome the limitations of conventional ADC technologies. The company's pipeline includes multiple programs targeting oncology, as well as other therapeutic areas such as antibiotics and anti-fibrotics. LigaChem Biosciences actively pursues global drug development through strategic partnerships, including co-development and licensing agreements with international pharmaceutical companies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-09 00:00
투자판단관련주요경영사항 (신규 항체-약물 결합체(ADC) 연구개발을 위한 공동연구 및 항체 기술도입 계약 체결)
Korean 10.5 KB
2025-08-26 00:00
투자판단관련주요경영사항 (LCB97관련 마일스톤 기술료 수령)
Korean 7.7 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 3.7 MB
2025-07-02 00:00
주식등의대량보유상황보고서(약식)
Korean 62.5 KB
2025-06-27 00:00
신탁계약에의한취득상황보고서
Korean 21.5 KB
2025-06-26 00:00
기업설명회(IR)개최
Korean 7.3 KB
2025-06-11 00:00
투자판단관련주요경영사항 ('LCB97'관련 마일스톤 기술료 수령)
Korean 8.7 KB
2025-06-05 00:00
투자판단관련주요경영사항 (신규 항체-약물 결합체(ADC) 연구개발을 위한 공동연구 및 항체 기술도입 계약 체결)
Korean 10.7 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean 2.5 MB
2025-05-13 00:00
투자판단관련주요경영사항 (신규 항체-약물 결합체(ADC) 연구개발을 위한 항체 기술도입 계약 체결)
Korean 10.5 KB
2025-04-15 00:00
자기주식처분결과보고서
Korean 21.4 KB
2025-04-11 00:00
신탁계약해지결과보고서
Korean 22.7 KB
2025-04-08 00:00
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 28.2 KB
2025-04-08 00:00
주요사항보고서(자기주식처분결정)
Korean 34.8 KB
2025-03-31 00:00
정기주주총회결과
Korean 20.5 KB

Automate Your Workflow. Get a real-time feed of all LigaChem Biosciences Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for LigaChem Biosciences Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for LigaChem Biosciences Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.